垂体腺瘤免疫微环境及免疫治疗的研究进展

doi:10.16352/j.issn.1001-6325.2022.01.034

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (1): 173-178.doi: 10.16352/j.issn.1001-6325.2022.01.034

垂体腺瘤免疫微环境及免疫治疗的研究进展

郭晓鹏, 幸兵^*, 马文斌

中国医学科学院北京协和医学院北京协和医院神经外科,北京 100730

收稿日期:2021-10-12 修回日期:2021-11-22 出版日期:2022-01-05 发布日期:2022-01-05
通讯作者: ^* xingbingemail@aliyun.com
基金资助:
教育部产学合作协同育人项目(202002277001)

Immune microenvironment and immunotherapy of pituitary adenomas

GUO Xiao-peng, XING Bing^*, MA Wen-bin

Department of Neurosurgery, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730, China

Received:2021-10-12 Revised:2021-11-22 Online:2022-01-05 Published:2022-01-05
Contact: ^* xingbingemail@aliyun.com

摘要/Abstract

摘要： 垂体腺瘤(PAs)是第二常见的原发性中枢神经系统肿瘤,多数可通过手术、药物或放射治疗治愈。但是,部分PAs经过传统治疗后仍反复复发并侵袭性生长,甚至发生远端转移,缩短了患者生存期并降低了生活质量。近年来,关于脑肿瘤免疫微环境的研究逐渐兴起,尤其在胶质瘤领域,为免疫治疗提供了潜在有效靶点,为提高患者生存创造了条件。但是,既往研究仅对PAs微环境中免疫细胞、免疫分子及细胞因子进行了初步分析,对动物和人PAs的免疫治疗研究刚刚起步。

关键词: 垂体腺瘤, 免疫微环境, 免疫治疗

Abstract: Pituitary adenomas (PAs) are the second most common primary central nervous system tumors. Although most PAs can be cured by surgical operation, medicine treatment or radiotherapy, some PAs may recur, invade adjacent structures or even metastasize to other organs after traditional treatments, so decreaseing patient overall survival and deteriorate their life quality. In recent years, studies on the immune microenvironment of brain tumors emerged, especially in the field of glioma, providing potential effective treatment targets for immunotherapy and setting the foundation for improving patient survival. However, previous studies have only conducted preliminary analyses on immune cells, immune molecules, and cytokines in the microenvironment of PAs. The research on immunotherapy of PAs with animal model and humans is only at an early phase.

Key words: pituitary adenoma, immune microenvironment, immunotherapy

中图分类号:

R739.41

郭晓鹏, 幸兵, 马文斌. 垂体腺瘤免疫微环境及免疫治疗的研究进展[J]. 基础医学与临床, 2022, 42(1): 173-178.

GUO Xiao-peng, XING Bing, MA Wen-bin. Immune microenvironment and immunotherapy of pituitary adenomas[J]. Basic & Clinical Medicine, 2022, 42(1): 173-178.

参考文献

[1]Ostrom QT, Patil N, Cioffi G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017[J]. Neuro Oncol, 2020, 22: iv1-iv96.
[2]Dai C, Liang S, Sun B, et al. The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas[J]. Front Endocrinol (Lausanne), 2020, 11: 608422. doi: 10.3389/fendo.2020.608422.
[3]Wang Z, Guo X, Gao L, et al. The immune profile of pituitary adenomas and a novel immune classification for predicting immunotherapy responsiveness[J]. J Clin Endocrinol Metab, 2020, 105: e3207-e3223. doi: 10.1210/clinem/dgaa449.
[4]Marques P, Grossman AB,Korbonits M. The tumour microenvironment of pituitary neuroendocrine tumours[J]. Front Neuroendocrinol, 2020, 58: 100852. doi: 10.1016/j.yfrne.2020.100852.
[5]Ilie MD, Vasiljevic A, Raverot G, et al. The microenvironment of pituitary tumors-biological and therapeutic implications[J]. Cancers (Basel), 2019, 11: 1605. doi: 10.3390/cancers11101605.
[6]Mei Y, Bi WL, Agolia J, et al. Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression[J]. Pituitary, 2021, 24: 359-373.
[7]Wang PF, Wang TJ, Yang YK, et al. The expression profile of PD-L1 and CD8(+) lymphocyte in pituitary adenomas indicating for immunotherapy[J]. J Neurooncol, 2018, 139: 89-95.
[8]Marques P, Barry S, Carlsen E, et al. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours[J]. Acta Neuropathol Commun, 2019, 7: 172. doi: 10.1186/s40478-019-0830-3.
[9]Mei Y, Bi WL, Greenwald NF, et al. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors[J]. Oncotarget, 2016, 7: 76565-76576.
[10]Iacovazzo D, Chiloiro S, Carlsen E, et al. Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours[J]. Endocrine, 2020, 67: 651-658.
[11]Barry S, Carlsen E, Marques P, et al. Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors[J]. Oncogene, 2019, 38: 5381-5395.
[12]Lu JQ, Adam B, Jack AS, et al. Immune cell infiltrates in pituitary adenomas: more macrophages in larger adenomas and more T cells in growth hormone adenomas[J]. Endocr Pathol, 2015, 26: 263-272.
[13]Sato M, Tamura R, Tamura H, et al. Analysis of tumor angiogenesis and immune microenvironment in non-functional pituitary endocrine tumors[J]. J Clin Med, 2019, 8: 695. doi: 10.3390/jcm8050695.
[14]Yagnik G, Rutowski MJ, Shah SS, et al. Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes[J]. Oncotarget, 2019, 10: 2212-2223.
[15]Giese MA, Hind LE,Huttenlocher A. Neutrophil plasticity in the tumor microenvironment[J]. Blood, 2019, 133: 2159-2167.
[16]Kemeny HR, Elsamadicy AA, Farber SH, et al. Targeting PD-L1 initiates effective antitumor immunity in a murine model of Cushing Disease[J]. Clin Cancer Res, 2020, 26: 1141-1151.
[17]Nomura R, Yoshida D,Teramoto A. Stromal cell-derived factor-1 expression in pituitary adenoma tissues and upregulation in hypoxia[J]. J Neurooncol, 2009, 94: 173-181.
[18]Arzt E, Buric R, Stelzer G, et al. Interleukin involvement in anterior pituitary cell growth regulation: effects of IL-2 and IL-6[J]. Endocrinology, 1993, 132: 459-467.
[19]Wu JL, Qiao JY,Duan QH. Significance of TNF-alpha and IL-6 expression in invasive pituitary adenomas[J]. Genet Mol Res, 2016, 15: 7502. doi: 10.4238/gmr.15017502.
[20]Lamb LS, Sim HW, McCormack AI. Exploring the role of novel medical therapies for aggressive pituitary tumors: a review of the literature-“are we there yet?”[J]. Cancers (Basel), 2020, 12: 308. doi: 10.3390/cancers12020308.
[21]Lin AL, Jonsson P, Tabar V, et al. Marked response of a hypermutated acth-secreting pituitary carcinoma to Ipilimumab and Nivolumab[J]. J Clin Endocrinol Metab, 2018, 103: 3925-3930.
[22]Caccese M, Barbot M, Ceccato F, et al. Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab[J]. Anticancer Drugs, 2020, 31: 199-204.
[23]Sol B, de Filette JMK, Awada G, et al. Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?[J]. Eur J Endocrinol, 2021, 184: K1-K5. doi: 10.1530/EJE-20-0151.
[24]Principe M, Chanal M, Ilie MD, et al. Immune lands-cape of pituitary tumors reveals association between macrophages and gonadotroph tumor invasion[J]. J Clin Endocrinol Metab, 2020, 105: 3459-3473.
[25]Tang X, Zhao S, Zhang Y, et al. B7-H3 as a novel CAR-T therapeutic target for glioblastoma[J]. Mol Ther Oncolytics, 2019, 14: 279-287.

垂体腺瘤免疫微环境及免疫治疗的研究进展

Immune microenvironment and immunotherapy of pituitary adenomas

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	周玥, 童安莉. 嗜铬细胞瘤/副神经节瘤免疫微环境[J]. 基础医学与临床, 2024, 44(6): 742-747.
[2]	刘宛榕, 赵林. 颅内生殖细胞肿瘤的药物治疗[J]. 基础医学与临床, 2024, 44(10): 1350-1356.
[3]	葛郁平, 刘莹, 赵林. 血管肉瘤药物治疗进展[J]. 基础医学与临床, 2024, 44(10): 1363-1367.
[4]	杨俊豪, 赵林. 恶性间皮瘤的靶向与免疫治疗[J]. 基础医学与临床, 2024, 44(10): 1342-1349.
[5]	颜晨红, 金儿. 外泌体PD-L1在非小细胞肺癌诊断和治疗上的研究进展[J]. 基础医学与临床, 2023, 43(9): 1457-1461.
[6]	代娣, 刘玉琴. 原发性胃淋巴瘤的诊断难点及治疗进展[J]. 基础医学与临床, 2023, 43(9): 1462-1466.
[7]	伍琦, 王绍波. CRISPR/Cas9技术在CAR-T细胞治疗肿瘤中作用的研究进展[J]. 基础医学与临床, 2023, 43(8): 1313-1316.
[8]	陈忠婕, 黄嘉如, 胡清, 赵珍琴, 陈俏俏, 孙浚源, 贾静. 免疫检查点CD276蛋白参与肿瘤发生发展作用机制的研究进展[J]. 基础医学与临床, 2023, 43(7): 1143-1147.
[9]	杨为祝, 刘忠, 张峰林, 黄延林, 孙瑾, 田新华. NOX4介导的氧化应激参与垂体腺瘤出血性卒中的发生[J]. 基础医学与临床, 2023, 43(7): 1040-1044.
[10]	李珍, 段昭君, 罗云萍. 神经节苷脂GD2可作为肺癌干细胞一个潜在的候选标志物[J]. 基础医学与临床, 2023, 43(5): 777-784.
[11]	李钊璇, 罗云萍, 陈翀. 气液交互法培养小鼠来源的肿瘤类器官的建立及优化[J]. 基础医学与临床, 2022, 42(5): 782-787.
[12]	李倩, 刘纯华, 王晨怡, 谈娇娇, 马玉萍, 吕海宏. 炎性因子调控1型糖尿病血管内皮细胞功能的研究进展[J]. 基础医学与临床, 2021, 41(10): 1497-1501.
[13]	李北芳高霞张朦琦葛赛李忠武沈琳高静. 运用组学手段探索EBV相关性与非相关性胃癌的可能差异分子[J]. 基础医学与临床, 2018, 38(7): 933-937.
[14]	童晨曦宋银宏. 嵌合抗原受体基因修饰的T细胞免疫治疗骨肉瘤的研究进展[J]. 基础医学与临床, 2018, 38(7): 1012-1015.
[15]	毛宁熊弢. 超声微泡介导Itch基因沉默增强T细胞对肺腺癌细胞LA795免疫杀伤作用[J]. 基础医学与临床, 2018, 38(4): 516-521.